Key result
PVS(RIPO), a recombinant oncolytic poliovirus, is emerging as a promising immunotherapeutic approach for glioblastoma multiforme, demonstrating safety and preliminary efficacy in early clinical trials.
Why the study?
Prognosis for glioblastoma multiforme remains grim with a median survival of 12-15 months, motivating the review of PVS(RIPO) as a novel immunotherapeutic approach.
PVS(RIPO) is a promising recombinant oncolytic poliovirus that demonstrates preclinical safety and efficacy, and preliminary clinical promise for the treatment of glioblastoma multiforme.
Should not yet change glioblastoma practice; hypothesis-generating for oncolytic virotherapy pending randomized trials.
While the prognosis for glioblastoma multiforme remains grim with a median survival of 12-15 months, PVS(RIPO), a recombinant oncolytic poliovirus, is emerging as a novel immunotherapeutic approach to treat malignancy. PVS(RIPO) is a genetically recombinant poliovirus-rhinovirus chimera that demonstrates antitumor efficacy via two main mechanisms: cytotoxicity and its subsequent immunogenenic response. Here, I review the rationale for oncolytic viruses in the treatment of glioblastoma, the development of PVS(RIPO), the underlying mechanisms of action of PVS(RIPO), the critical preclinical trial that demonstrated its safety and efficacy, the ongoing clinical trials that have shown promising preliminary data, and limitations of PVS(RIPO) as an oncolytic virus for glioblastoma therapy.
No takes yet. Share an insight, caveat, or question.
Austin B. Carpenter (2019) conducted a review in Glioblastoma multiforme. PVS(RIPO) was evaluated. PVS(RIPO), a recombinant oncolytic poliovirus, is emerging as a promising immunotherapeutic approach for glioblastoma multiforme, demonstrating safety and preliminary efficacy in early clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: